Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018/06/01 by Paolo Caraceni, Oliviero Riggio, Paolo Angeli +111 · 4 citations
Medicine · #Albumin #Ascites #Cirrhosis #Clinical endpoint #Clinical trial #Confidence interval #Gastroenterology #Hazard ratio #Intention-to-treat analysis #Internal medicine #Liver Disease Diagnosis and Treatment #Liver Disease and Transplantation #Liver Diseases and Immunity #Medicine #Randomized controlled trial #Surgery

paper · pdf · doi:10.1016/s0140-6736(18)30840-7

crossref issued 2018/06/01 · crossref published 2018/06/01 · crossref published-print 2018/06/01 · openalex publication_date 2018/06/01 · crossref created 2018/06/01 · crossref deposited 2018/08/02 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/06 · crossref indexed 2026/08/06

Citations

• C308 気象情報の提供タイミング(気象予報との関連を踏まえた)等について(スペシャル・セッション「気象情報・知識の伝達・普及(III)」,一般口頭発表)
• Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
• Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015

Cited by

• Expert consensus on the use of human serum albumin in critically ill patients
• Anemia and hypoalbuminemia are associated with hepatic encephalopathy and mortality after portal hypertension-related bleeding
• Controversies regarding albumin therapy in cirrhosis
• Human serum albumin [wikipedia]